Grants and Contributions:
Title:
MNC Collab - DispersinB Wound Gel - DispersinB Wound Gel Development and Commercialization
Agreement Number:
1022709
Agreement Value:
$75,000.00
Agreement Date:
Sep 2, 2024 - Feb 21, 2025
Description:
As part of Multinational Corporate Collaboration Program, the project “DispersinB Wound Gel Development and Commercialization” will focus on scaling up the manufacturing process for DispersinB Wound Gel and ensuring the product meets specifications. The DispersinB Wound Gel is a combination product (device, drug, biologic) that is first of its kind in wound care as it disperses biofilms enzymatically.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Winnipeg, Manitoba, CA R3T 6G2
Reference Number:
172-2024-2025-Q2-1022709
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
884326117
Recipient Type:
For-profit organization
Recipient's Legal Name:
Kane Biotech Inc.
Federal Riding Name:
Winnipeg South
Federal Riding Number:
46013
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410